Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.9741
- Book/Share 2.5079
- PB 19.8496
- Debt/Equity 1.856
- CurrentRatio 4.9795
- ROIC 0.1086
- MktCap 10834216669.0
- FreeCF/Share 0.5326
- PFCF 90.6583
- PE 57.6918
- Debt/Assets 0.5562
- DivYield 0
- ROE 0.3817
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | HIMS | KeyBanc Capital Markets | -- | Sector Weight | -- | -- | Oct. 21, 2025 |
| Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Hims & Hers Q3 Preview: Key Metrics I Want To See For Beating 2030 Guidance
Published: October 21, 2025 by: Seeking Alpha
Sentiment: Positive
I expect Hims & Hers Health, Inc. to show stabilizing ARPU around $54+ per user in Q3 despite the GLP-1 slowdown, which could signal meaningful upside to the company's conservative 2030 guidance. I'm anticipating a slight margin dip in Q3. Margins should then stabilize thanks to 1-3% annual marketing leverage gains that support subscriber growth without added costs. In my view, HIMS is already surpassing implied 2030 ARPU targets, and expansions into menopause, hormone health, and personalized plans will help it beat guidance ahead of time.
Read More
Hims & Hers: Q3 Could Provide Volatility, But The Long-Term Vision Remains Bright
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers (HIMS) is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers. HIMS has aggressively captured market share, often operating in a legal 'grey area' regarding compounded obesity drugs. Recent FDA policy changes ending temporary compounding allowances raise questions about HIMS's continued ability to offer these treatments.
Read More
Hims & Hers Health: Roller Coaster Gift
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target. Recent product launches, including at-home lab testing, are expected to boost ARPU and drive significant revenue growth for HIMS in coming years. The stock market over reacted to planned stock sells by the CEO.
Read More
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks is more attractive to value investors?
Read More
Is Trump Going to Kill the GLP-1 Cash Cow?
Published: October 17, 2025 by: 24/7 Wall Street
Sentiment: Negative
GLP-1 drugs propelled Novo Nordisk (NVO) and Eli Lilly (LLY) to record profits, with sales exceeding $20 billion amid skyrocketing demand. Both companies cut prices recently to expand access, but President Trump's vow threatens deeper reductions.
Read More
Hims & Hers Elevates Technology-Driven Healthcare Accessibility
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS boosts AI-led care with new technology chief, hormone therapies and a global push via its ZAVA acquisition.
Read More
Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem
Published: October 16, 2025 by: Benzinga
Sentiment: Positive
Hims & Hers Health Inc. (NYSE:HIMS) has become one of 2025's most surprising winners, up more than 150% year-to-date and over 200% in the past twelve months. But what's making Wall Street sit up this time is not another flashy partnership — it's a rally built from within.
Read More
Hims & Hers: Ramping Up A New Billion-Dollar Segment (Rating Upgrade)
Published: October 16, 2025 by: Seeking Alpha
Sentiment: Neutral
I am upgrading Hims & Hers Health, Inc. to a Buy with an $80 price target, implying 30% upside. The new 'Hers' specialty in Menopause is expected to help the company drive over $1B in Hers segment revenue by 2026, diversifying away from GLP-1 volatility. Despite a recent sequential revenue decline and negative cash flow, Hims & Hers maintains strong subscriber growth and ambitious 2030 targets as it builds a full-spectrum personalized healthcare platform.
Read More
How HIMS Stock Rises To $120?
Published: October 16, 2025 by: Forbes
Sentiment: Positive
Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is creating revenue sources beyond its debated compounded GLP-1 obesity treatments. With shares already up 150% year-to-date and trading at approximately $60, the critical question now is: could HIMS stock go up another 2x to $120?
Read More
Weight-loss drugs shook up the stock market. Menopause treatments could be next.
Published: October 15, 2025 by: Market Watch
Sentiment: Positive
Hims & Hers is taking aim at menopause and perimenopause in an attempt to tap in to a huge and potentially highly lucrative market.
Read More
Hims & Hers to Offer Treatments for Menopause, Perimenopause
Published: October 15, 2025 by: WSJ
Sentiment: Positive
The company expects the new specialty to help the Hers unit to surpass $1 billion in annual revenue next year.
Read More
Hims & Hers Gains 3.8% in 3 Months: Time to Hold the Stock or Sell?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
HIMS expands into men's health and hormones, but rising costs and regulatory hurdles threaten its momentum.
Read More
Hims & Hers: Why I'm Betting On HIMS Heading To $100
Published: October 13, 2025 by: Seeking Alpha
Sentiment: Positive
I see a clear path for Hims & Hers Health to reach $100 a share, and I plan to be there when it gets there. HIMS expects revenue growth to rebound, driven by weight loss and new health offerings, aiming for 30%+ growth in 2026. Despite a temporary dip into negative free cash flow, HIMS maintains strong profitability targets and trades at an attractive 24x forward free cash flow.
Read More
Hims & Hers Expands Personalized Care Access Via Telehealth Platform
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its AI-powered telehealth platform, boosting personalized care and eyeing international growth in 2026.
Read More
How Hims & Hers founder Joe Spector turned 10 failures into $1B idea
Published: October 09, 2025 by: Yahoo Finance
Sentiment: Positive
Listen and subscribe to The Big Idea with Elizabeth Gore on Apple Podcasts, Spotify, or wherever you find your favorite podcast. How do you break into a tough market and win?
Read More
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Oct. 3, 2025 /PRNewswire/ -- Berger Montague , a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Novo Nordisk A/S's termination of its partnership with Hims & Hers. Shareholders of HIMS & HERS may learn more about this investigation by contacting Berger Montague: Radha Raghavan at [email protected] or (332) 271-8908, or Andrew Abramowitz at [email protected] or (215) 875-3015 or by …
Read More
Hims & Hers Expands Health Access Through Subscription Revenue Model
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS boosts predictable revenue and customer loyalty with a flexible, subscription-based model across key health categories.
Read More
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Hims & Hers: Growth Meets FDA Scrutiny And Tariff Risks
Published: September 26, 2025 by: Seeking Alpha
Sentiment: Negative
Hims & Hers Health, Inc. has shown strong growth, overcoming partnership fallout and posting a 73% year-over-year revenue surge, but faces execution and regulatory risks. HIMS stock's premium valuation reflects high growth expectations, leaving little room for missteps amid FDA scrutiny of compounded GLP-1 marketing and new tariff uncertainties. I'm expecting Hims & Hers to see near-term volatility followed by a break as uncertainty around tariffs and the FDA settles.
Read More
Hims & Hers Powers YieldMax's Latest Options-Based Income ETF
Published: September 26, 2025 by: Benzinga
Sentiment: Positive
YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY).
Read More
HIMS vs. DOCS: Which Digital Health Platform Is a Better Investment?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers and Doximity are transforming digital health, but which leads in earnings growth and platform expansion? Let's see.
Read More
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Kuehn Law Encourages Investors of Hims & Hers Health, Inc. to Contact Law Firm
Published: September 24, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Hims & Hers Health, Inc. (NYSE: HIMS) breached their fiduciary duties to shareholders.
Read More
Hims & Hers Expands Care Ecosystem via Global and Digital Innovation
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS is scaling globally with AI-powered care, new treatments and an $870 million boost to expand its digital ecosystem.
Read More
Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties
Published: September 19, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Sept. 19, 2025 /PRNewswire/ -- Berger Montague , a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Novo Nordisk A/S's termination of its partnership with Hims & Hers.
Read More
Telehealth Stock Looks Primed for a Short Squeeze
Published: September 19, 2025 by: Schaeffers Research
Sentiment: Positive
Subscribers to Schaeffer's Weekend Trader options recommendation service received this HIMS commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry and exit parameters.
Read More
Hims & Hers Health: Bumpy Ride Will End
Published: September 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers Health has traded very volatile over the last year as the market misunderstand the business opportunity beyond GLP-1s and weight-loss drugs. The online health and wellness faces FDA scrutiny, but this is industry-wide and not unique to the company. The platform is rapidly growing subscribers, launching new offerings, and targeting large under-penetrated markets domestically and internationally in a path to hitting a $6.5B 2030 sales target.
Read More
Hims & Hers Expands AI and Technology Focus to Advance Digital Care
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Andrew Dudum
- Employees 1637